Abstract: blocking PD-L2 in mice reduced senescent cells and improved insulin sensitivity and grip strength
In this abstract, PD-L2 was upregulated in isolated senescent human cells and during aging; old PD-L2 knockout mice accumulated fewer senescent cells and showed greater insulin sensitivity and grip strength than old wild-type mice, and anti-PD-L2 therapy restored insulin sensitivity in aged wild-type mice. [1]
Automatic summary · not editorially reviewed
The key findings
PD-L2 was upregulated in isolated senescent human cells and during aging, and senolytics can remove age-associated senescent cells with high PD-L2 expression. [1]
Old PD-L2 knockout mice accumulated fewer senescent cells than old wild-type mice and had greater insulin sensitivity and grip strength. [1]
Anti-PD-L2 therapy restored insulin sensitivity in aged wild-type mice, and targeting PD-L2 is proposed as a possible strategy against age-related dysfunction. [1]
The source at a glance
- Study type / format
- Abstract of a preclinical and cell-based study
- Population / context
- Isolated senescent human cells, aging mice (wild-type and PD-L2 knockout) and aged wild-type mice.
- Summary based on
- Study abstract
- Original publication
- September 10, 2026
PD-L2 in senescent human cells and aging
The abstract reports that PD-L2 was upregulated in isolated senescent human cells and during aging. It also states that senolytics can remove age-associated senescent cells that express high levels of PD-L2. The authors describe PD-L2 as an immune checkpoint on senescent cells that lets them evade immune clearance and persist during aging. These are findings reported in the abstract, not a demonstration of a treatment for people.
Supporting source [1]
Old knockout mice: fewer senescent cells, better measures
Old PD-L2 knockout mice accumulated fewer senescent cells than old wild-type mice, and their insulin sensitivity and grip strength were greater. In aged wild-type mice, anti-PD-L2 therapy restored insulin sensitivity. These comparisons are between mice; the abstract does not report human outcomes for blocking PD-L2.
Supporting source [1]
Abstract-only scope and proposed strategy
The authors propose that targeting PD-L2 in senescent cells may be a strategy for alleviating age-related dysfunction linked to cellular senescence. This is a proposal, not a validated therapy. Only the abstract was reviewed; the full text was not reviewed, so design details, sample sizes, follow-up and statistical uncertainty are not available here.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Design details, sample sizes, follow-up and statistical uncertainty are not reported in the supplied text. Mouse and isolated-cell findings do not establish human benefits, and the proposed strategy is not a validated therapy.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Chaib S, Langhi Prata LGP, Suda M, Sola A, Mitchell TJ, Anastasiadis ZP, Kunz HE, Nie J, Victorelli SG, Lozano Flores R, Weigl M, Kawamoto S, Uemura K, Kim H, Wang B, Inman CL, Pirtskhalava T, Giorgadze N, Xue A, Johnson KO, Espindola-Netto JM, Suvakov S, Hatamova J, Parker ES, Hartono DB, Kulshreshtha V, Lopez-Dominguez JA, Deisinger AM, Palmer AK, Zhu Y, Weivoda MM, Gingery A, Hromas R, Garovic VD, Passos JF, Allison DB, Hara E, Jensen MD, Musi N, Tullius SG, Ronai ZA, Serrano M, Xu M, Lanza IR, Ikeno Y, Tchkonia T, Kirkland JL. · europepmc.org · September 10, 2026